 |
|
| Systematic (IUPAC) name | |
|---|---|
| S-(fluoromethyl)-6α,9-difluoro-11β, 17-dihydroxy-16α-methyl-3-oxoandrosta-1, 4-diene-17β-carbothioate, 17-propionate | |
| Identifiers | |
| CAS number | 80474-14-2 |
| ATC code | D07AC17 & D07AC04 (topical) |
| PubChem | 5311101 |
| DrugBank | APRD00065 |
| Chemical data | |
| Formula | C25H31F3O5S |
| Mol. mass | 500.57 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 0.51% (Intranasal) |
| Protein binding | 91% |
| Metabolism | Intranasal Hepatic (CYP3A4-mediated) |
| Half life | 10 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C for Intranasal and Inhaled |
| Legal status | |
| Routes | Intranasal, Inhaled, Topical Cream or Ointment |
 (what is this?) (verify) |
|
Fluticasone propionate is a synthetic corticosteroid derived from fluticasone used to treat asthma and allergic rhinitis.
GlaxoSmithKline currently markets fluticasone propionate as Flovent (USA and Canada) and Flixotide (EU) for asthma, and as Flonase (USA and Canada) Flixonase (EU and Brazil) for allergic rhinitis, as well as a combination of fluticasone and salmeterol as Advair (USA and Canada) or Seretide (EU).
It is also available as a cream (marketed as Cutivate or Flutivate) for the treatment of eczema and psoriasis.
Contents |
Flonase patent issues
GlaxoSmithKline's patent on Flonase expired in May 2004. The Food and Drug Administration (FDA) approved the sale of a generic version of Flonase on February 22, 2006. On February 23, 2006, GlaxoSmithKline (GSK) was able to obtain a temporary 10-day restraining order from a federal judge in Baltimore blocking the shipment and sales of the approved generic versions of Flonase. The restraining order lasted until March 6, 2006. The basis of the complaint by GSK was that the FDA failed to follow its own regulations in approving the generics and failed to apply the same quality standards for the generic version as it did for Flonase. GSK made these arguments in petitions filed with the FDA, but the FDA rejected those petitions. The Maryland District Court denied the request by GSK to extend the ban on Flonase generics beyond March 6, 2006, and GSK released a statement that they would not appeal the ruling.[1] The ruling meant that sales of generic versions of Flonase could proceed.
Side Effects
In studies the topical drug has been shown to cause burning, stinging, skin irritation, blisters, dryness, skin infection, infected eczema, viral warts, impetigo, atopic dermatitis, pruritus, exacerbation of pruritus, exacerbation of eczema, erythema, and folliculitis. [2]
Side effects of the nostril spray version include headache, throat infection, nasal irritation, sneezing, cough, nausea, vomiting, nosebleeds, skin rash, itching, facial swelling, and anaphylaxis. It can also cause growth suppression in children.[3]
See also
References
|
|||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
